Oncocross Co., Ltd. announced that it expects to receive KRW 15.00002592 billion in funding from InterVest Co., Ltd., Dongwha Pharm.Co.,Ltd and other investors.
September 24, 2023
Share
Oncocross Co., Ltd. announced a private placement of 1,482,216 Registered Preferred Stock at an issue price of KRW 10,120 per share for the gross proceeds of KRW 15,000,025,920 on September 25, 2023. The transaction will include participation from new investors InterVest Deeptech Investment Fund and InterVest Open Innovation PEF,funds managed by InterVest Co., Ltd.,Dongwha Pharm.Co.,Ltd,Pathfinder Green Bio Investment Fund and ST-Moru New Technology Fund 1. The Registered Preferred Stock will be 100% convertible into common shares of the company at a fixed conversion price of KRW 10,120 per share from October 30, 2023 to October 29, 2033. The company will issue Registered Preferred Stock through Third-party capital increase.
The transaction has been approved by the board of directors of the company. The payment date is on October 27, 2023.
DONGWHA PHARM.CO., LTD is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products consist of ethical drugs, including digestive system remedies, antibiotics, cardiovascular and metabolic disease treatments, non steroidal anti-inflammatory drugs, respiratory remedies, muscle relaxants, nervous system remedies, dermatological remedies and urinary system remedies, and over-the-counter (OTC) drugs, including cold remedies, dental remedies, dermatological remedies, hepatic protectors, nutrients, tonics, topical analgesics, anti-smoking agents and others. It also provides medicine raw materials, health food and drinks, as well as cosmetics. The Company distributes its products within domestic market and to overseas markets.
Oncocross Co., Ltd. announced that it expects to receive KRW 15.00002592 billion in funding from InterVest Co., Ltd., Dongwha Pharm.Co.,Ltd and other investors.
DONGWHA PHARM.CO.,LTD 
